Shopping Cart
- Remove All
- Your shopping cart is currently empty
Pozelimab (REGN 3918) is a humanized antibody targeting component 5 (C5), used for research on Pozelimab disease.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $328 | In Stock | |
5 mg | $993 | In Stock | |
10 mg | $1,570 | In Stock | |
25 mg | $2,330 | In Stock | |
50 mg | $3,150 | In Stock |
Description | Pozelimab (REGN 3918) is a humanized antibody targeting component 5 (C5), used for research on Pozelimab disease. |
In vitro | The Kd values of Pozelimab binding to human C5 and cyborg monkey C5 were 262 pM and 8.55 nM, and the IC50 values were 2.8 nM and 20 nM, respectively. Pozelimab blocks alternative pathway (AP) -mediated hemolysis in normal and cynomolophoric monkeys with IC50 values of 26 and 8.9 nM, respectively. [1] |
In vivo | Pozelimab (5 or 10 mg/kg, injected subcutaneously) has a half-life of 12.9-13.3 days in cynophilic monkeys. [2] Pozelimab (15 mg/kg, injected subcutaneously) showed prolonged pharmacokinetics and pharmacodynamics in both mice and cynophagous monkeys, and blocked complement mediated in vitro hemolysis activity for at least 35 days. [1] |
Alias | REGN3918, REGN 3918 |
Cas No. | 2096328-94-6 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.